MDxHealth SA Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.8%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.46next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Core Prostate Cancer Revenue Quarterly23.9MTarget: 110000000 to 115000000
Liquid-based Test Volume Quarterly26.2K
Tissue-based Test Volume Quarterly11.1K
Watch Items
- Medicare Recoupment Demand from NovitasTrigger: $10.4 millionAction: Vigorously contest through the formal Medicare appeals process and monitor impact on cash reserves.
- Resolve UTI Business Restructuring and Exit CostsTrigger: Finalization of wind-down chargesAction: Monitor severance, lease-related charges, asset impairments, and contract termination expenses.
- Adjusted EBITDA Margin Run RateTrigger: 10% exiting 2026Action: Track operating leverage, productivity improvements, and commercial execution post-ExoDx integration.
Research as of 20 Jun 2026